BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 517 filers reported holding BIO-TECHNE CORP in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $60,022,802 | -22.9% | 881,779 | -7.6% | 0.02% | -16.0% |
| Q2 2023 | $77,863,096 | +14.7% | 953,853 | +4.2% | 0.02% | +4.2% |
| Q1 2023 | $67,898,612 | -17.5% | 915,200 | -7.8% | 0.02% | -25.0% |
| Q4 2022 | $82,279,242 | +20.1% | 992,752 | +311.7% | 0.03% | +18.5% |
| Q3 2022 | $68,487,000 | -21.3% | 241,153 | -4.0% | 0.03% | -12.9% |
| Q2 2022 | $87,076,000 | -26.5% | 251,201 | -8.2% | 0.03% | -13.9% |
| Q1 2022 | $118,499,000 | -14.2% | 273,645 | +2.6% | 0.04% | -14.3% |
| Q4 2021 | $138,045,000 | +4.3% | 266,837 | -2.3% | 0.04% | -2.3% |
| Q3 2021 | $132,356,000 | +54.8% | 273,141 | +43.9% | 0.04% | +48.3% |
| Q2 2021 | $85,478,000 | +151.4% | 189,842 | +113.2% | 0.03% | +123.1% |
| Q1 2021 | $34,006,000 | +26.7% | 89,037 | +5.3% | 0.01% | +18.2% |
| Q4 2020 | $26,841,000 | -27.0% | 84,525 | -43.0% | 0.01% | -31.2% |
| Q3 2020 | $36,762,000 | +58.4% | 148,397 | +68.9% | 0.02% | +45.5% |
| Q2 2020 | $23,205,000 | +37.4% | 87,875 | -1.4% | 0.01% | +10.0% |
| Q1 2020 | $16,894,000 | -13.0% | 89,093 | +0.7% | 0.01% | +11.1% |
| Q4 2019 | $19,412,000 | +19.6% | 88,432 | +6.6% | 0.01% | 0.0% |
| Q3 2019 | $16,230,000 | -4.7% | 82,943 | +1.6% | 0.01% | 0.0% |
| Q2 2019 | $17,025,000 | +79.7% | 81,662 | +71.2% | 0.01% | +80.0% |
| Q1 2019 | $9,474,000 | +43.7% | 47,713 | +4.8% | 0.01% | 0.0% |
| Q4 2018 | $6,591,000 | -26.5% | 45,549 | +3.7% | 0.01% | -16.7% |
| Q3 2018 | $8,963,000 | +39.7% | 43,912 | +1.2% | 0.01% | +20.0% |
| Q2 2018 | $6,416,000 | -3.8% | 43,371 | -1.8% | 0.01% | 0.0% |
| Q1 2018 | $6,668,000 | +36.2% | 44,150 | +16.8% | 0.01% | +25.0% |
| Q4 2017 | $4,897,000 | +19.3% | 37,801 | +11.3% | 0.00% | +33.3% |
| Q3 2017 | $4,105,000 | +14.6% | 33,953 | +11.3% | 0.00% | 0.0% |
| Q2 2017 | $3,583,000 | +45.2% | 30,496 | +25.6% | 0.00% | +50.0% |
| Q1 2017 | $2,468,000 | +120.6% | 24,288 | +123.0% | 0.00% | +100.0% |
| Q4 2016 | $1,119,000 | +86.5% | 10,890 | +98.8% | 0.00% | 0.0% |
| Q3 2016 | $600,000 | +8.1% | 5,479 | +11.4% | 0.00% | 0.0% |
| Q2 2016 | $555,000 | +24.4% | 4,919 | +4.4% | 0.00% | – |
| Q1 2016 | $446,000 | +23.2% | 4,712 | +17.2% | 0.00% | – |
| Q4 2015 | $362,000 | +6.5% | 4,019 | +9.3% | 0.00% | – |
| Q3 2015 | $340,000 | +0.6% | 3,677 | +7.3% | 0.00% | – |
| Q2 2015 | $338,000 | +68.2% | 3,428 | +71.1% | 0.00% | – |
| Q1 2015 | $201,000 | +142.2% | 2,003 | +123.5% | 0.00% | – |
| Q4 2014 | $83,000 | – | 896 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |